XLO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XLO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:
We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.
Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
As of today (2024-05-30), Xilio Therapeutics's share price is $0.93. Xilio Therapeutics's GF Value is $0.00. Therefore, Xilio Therapeutics's Price-to-GF-Value for today is .
Based on the relationship between the current stock price and the GF Value, GuruFocus believes Xilio Therapeutics is Not Valued.
Xilio Therapeutics (NAS:XLO) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:
Posssible Evaluations | All-in-One Screener Examples (2) |
Possible Value Trap, Think Twice (1) | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (3) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (3) | Predictable High Quality Companies which are Significantly Undervalued |
(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) There is only a sufficient margin of safety when the stock is undervalued.
Xilio Therapeutics's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 0.93 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Xilio Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Katarina Luptakova | officer: Chief Medical Officer | C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451 |
Christopher James Frankenfield | officer: Chief Operating Officer | C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451 |
Kevin M. Brennan | officer: SVP, FINANCE AND ACCOUNTING | C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451 |
Edward C English | officer: Principal Accounting Officer | 828 WINTER STREET, WALTHAM MA 02451 |
Tomas J. Heyman | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Robert W. Ross | director | C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139 |
Yuan Xu | director | C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Bain Capital Life Sciences Fund Ii, L.p. | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Atlas Venture Opportunity Fund I, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Sv7 Impact Medicine Fund Lp | 10 percent owner | 71 KINGSWAY, LONDON X0 WC2B 6ST |
Bcls Ii Investo (gp), Llc | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Bcls Ii Investco, Lp | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Bain Capital Life Sciences Investors Ii, Llc | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Rivervest Venture Fund Iv, L.p. | 10 percent owner | 101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105 |
From GuruFocus
By sperokesalga sperokesalga • 03-02-2023
By sperokesalga sperokesalga • 02-27-2023
By GuruFocusNews GuruFocusNews • 06-17-2022
By GlobeNewswire • 09-27-2023
By Stock market mentor Stock market mentor • 02-02-2023
By GuruFocusNews GuruFocusNews • 06-07-2022
By Value_Insider Value_Insider • 11-23-2022
By Marketwired • 09-05-2023
By Value_Insider Value_Insider • 11-04-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.